Gonadorelin 10mg Nasal Spray

Gonadorelin nasal spray supplies the decapeptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, CAS 33515-09-2, molecular weight 1182.29. This is native gonadotropin-releasing hormone rather than an analogue of it, and its defining property is that the same molecule produces opposite outcomes depending on how it arrives.

Specification Table

Why Does Gonadorelin Nasal Spray Depend on Delivery Rhythm?

Gonadorelin nasal spray has a property almost nothing else in this catalogue shares. It makes format a pharmacological variable rather than a convenience.

Native GnRH is released from the hypothalamus in discrete pulses roughly every sixty to ninety minutes, and the receptor is built to read that rhythm.

Delivered in pulses, the compound stimulates gonadotropin release. Delivered continuously at the same total amount, it does the opposite and suppresses it.

The mechanism is receptor desensitisation and downregulation. Sustained occupancy uncouples the receptor from its signalling machinery and reduces surface expression.

That is not a side observation. It is the single most important pharmacological fact about this molecule, established by Knobil and colleagues in work that reshaped reproductive endocrinology.

For an experiment the consequence is direct. Two studies using identical amounts of this compound can report opposite results if one delivered it in pulses and the other did not.

A nasal spray delivers a bolus that is absorbed over some interval. That interval is not the same as an intravenous pulse or a continuous infusion.

Any study using this format needs to characterise its own delivery kinetics rather than assume them, because the kinetics determine the direction of the result.

What Does the Pyroglutamate Terminus Do?

The first residue is not an ordinary amino acid, and its formation is a step where preparations go wrong.

Pyroglutamate is glutamine whose side chain has cyclised back onto the backbone nitrogen, forming a five-membered ring and releasing ammonia.

That cyclisation removes the free amino group entirely. That is what blocks aminopeptidases from finding a starting point.

Combined with the glycinamide at the other end, the molecule has no free terminus at all, which is why its degradation happens by endopeptidase cleavage in the middle rather than from the ends.

The verification consequence is specific. An uncyclised preparation retaining glutamine sits 17 daltons heavier at roughly 1199, since cyclisation loses ammonia.

Seventeen daltons is comfortably resolved. A preparation carrying substantial uncyclised material is a different molecule with a free amino terminus and much shorter survival.

Cyclisation can also occur spontaneously in solution over time, so a preparation can drift toward the correct structure rather than away from it, which is unusual.

Asking whether the certificate reports a species near 1199 is the specific question for this compound and it takes one line to answer.

Where Does the Molecule Break?

With both termini blocked, degradation has to start somewhere in the middle. The position is known precisely.

A GnRH-specific endopeptidase cleaves between the glycine at position 6 and the leucine at position 7, which is the principal route in vivo.

That single bond accounts for the very short circulating half-life reported for this compound, measured in minutes rather than hours.

It is also the reason every long-acting GnRH analogue substitutes something at position 6. Replace the glycine and the enzyme loses its substrate.

Triptorelin, elsewhere in this range, does exactly that using D-tryptophan, which is why it survives far longer than the native sequence.

For a research preparation the practical point is that this compound is the short-lived member of its family by design rather than by deficiency.

Anyone comparing it against a substituted analogue is comparing durability as much as receptor engagement, and separating those requires attention to timing.

In an aqueous product the enzymatic route is absent unless contamination introduces it. So solution stability is governed by ordinary hydrolysis rather than by that specific enzyme.

One further consequence of that cleavage site is worth drawing out, because it explains an oddity in the published record.

Fragments produced by the endopeptidase are not all inert. The GnRH(1-5) fragment generated by that cut has its own reported activity in the literature, acting through a separate receptor.

That means degradation of this compound does not simply remove it from the system. It produces a second species with its own pharmacology.

For an experiment running long enough for meaningful degradation, the observed effect may reflect a mixture rather than the parent compound alone.

Nothing equivalent applies to the substituted analogues, since blocking the cleavage site also stops the fragment forming at all.

That is a further reason why comparing this compound against a position 6 analogue is not a clean potency comparison, and it is rarely acknowledged.

What Is the Actual Regulatory Position?

The generic statement that no approved formulation exists would be wrong here, and the accurate position is worth setting out carefully.

A human diagnostic preparation was approved in the United States as Factrel in 1982, used for assessing anterior pituitary gonadotrope function.

That human preparation has since been discontinued and withdrawn from the United States market, so it is not currently available for human use.

A separate and active FDA veterinary approval exists. An injectable gonadorelin preparation is approved for use in cattle, restricted to use by or on the order of a licensed veterinarian.

So this molecule holds a current approval in the United States, in animals, by injection, under veterinary control.

This product is none of those things. It is a research chemical supplied as a nasal spray, and it is not the approved veterinary injectable in a different container.

The distinction matters when reading the literature, because a substantial share of the record concerns approved preparations given parenterally under defined protocols.

Stating this precisely rather than defaulting to the boilerplate is the difference between an accurate page and a page that overclaims in the direction of caution, which is still overclaiming.

How Does 1182 Daltons Affect the Nasal Route?

Molecular weight is the strongest single predictor of transnasal transport, and gonadorelin nasal spray sits just above the useful threshold.

The practical transition is near 1,000 daltons, where paracellular passage between epithelial cells becomes inefficient.

At 1182.29 daltons this compound is above that line, larger than melanotan II at 1,024 and smaller than kisspeptin-10 at 1,302.

Being above the threshold means a smaller delivered fraction and wider variance between applications, which raises the replicate count an experiment needs.

The arginine and histidine give a net positive charge at physiological pH, and cationic molecules bind a negatively charged mucosal surface rather than passing through it.

Nasal delivery of GnRH analogues has a real clinical history, and preparations of related compounds have been used by this route, so the approach is not novel even where data for this specific molecule is thin.

Published intranasal pharmacokinetic data for the native sequence specifically is limited, and the delivery-rhythm question above matters more here than the absorbed fraction does.

What Should a Gonadorelin Certificate Contain?

A gonadorelin nasal spray certificate needs two entries that a generic peptide specification would miss.

Measured mass against 1182.29, with a specific check for a species near 1199 indicating uncyclised glutamine at the amino terminus.

Sequence stated explicitly, since several closely related GnRH analogues differ from this one at a single position and a trade name does not distinguish them.

Purity by reversed-phase chromatography, with the gradient written out on the certificate. The tryptophan and tyrosine give a genuine chromophore, so 280 nanometre detection is meaningful.

Oxidation check on the tryptophan at position 3, which would appear as a species near 1198 for a single oxygen addition. That figure sits close to the uncyclised mass, so resolution matters.

Counterion identity, quoted alongside net peptide content. At 1182.29 daltons a single trifluoroacetate at 114 is roughly 9 percent of the associated mass.

A statement on the related analogues, since triptorelin at 1311.45 differs by one substituted residue and is a plausible carryover contaminant on shared equipment.

That near-coincidence between the oxidised and uncyclised masses is the subtlest analytical point on this page, and it is one a low-resolution instrument would miss entirely.

How Should Gonadorelin Nasal Spray Be Stored and Recorded?

Storage requirements for gonadorelin nasal spray follow from one oxidation-prone residue and one blocked pair of termini.

Keep the bottle between 2 and 8 degrees Celsius, protected from light, and do not freeze a solution-state product.

The tryptophan at position 3 is the vulnerable feature, so light protection is a real requirement rather than a generic instruction.

Both termini are blocked, which removes exopeptidase susceptibility even if contamination introduces enzyme activity.

There is no cysteine and no methionine, so the thiol and thioether oxidation routes do not apply.

Serine and tyrosine hydroxyls are chemically quiet under ordinary storage, and the principal solution-state concern beyond tryptophan is microbial growth in an opened container.

Record the lot, the stated concentration, the date first opened, the storage temperature, the actuation count and, for this compound above all, the timing pattern of each application.

Timing is part of the experimental record here in a way it is not for any other product in this range, because the rhythm determines the direction of the result.

Published Literature

Selected references verified against the publisher record.

1. (‘Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53-88.’, ‘https://doi.org/10.1016/b978-0-12-571136-4.50008-5’)
2. (‘Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631-633.’, ‘https://doi.org/10.1126/science.100883’)
3. (‘Matsuo H, Baba Y, Nair RM, et al. Structure of the porcine LH- and FSH-releasing hormone. Biochem Biophys Res Commun. 1971;43(6):1334-1339.’, ‘https://doi.org/10.1016/S0006-291X(71)80019-0’)
4. (‘Millar RP, Lu ZL, Pawson AJ, et al. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25(2):235-275.’, ‘https://doi.org/10.1210/er.2003-0002’)

Frequently Asked Questions